Compare OSCR & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OSCR | PCVX |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United States |
| Employees | 2305 | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 7.0B |
| IPO Year | 2021 | 2020 |
| Metric | OSCR | PCVX |
|---|---|---|
| Price | $24.56 | $47.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | $16.88 | ★ $88.25 |
| AVG Volume (30 Days) | ★ 7.7M | 1.6M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.07 | N/A |
| Revenue | ★ $11,701,427,000.00 | N/A |
| Revenue This Year | $63.89 | N/A |
| Revenue Next Year | $5.30 | N/A |
| P/E Ratio | $11.40 | ★ N/A |
| Revenue Growth | ★ 27.50 | N/A |
| 52 Week Low | $10.69 | $29.10 |
| 52 Week High | $25.58 | $65.00 |
| Indicator | OSCR | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 63.54 | 37.91 |
| Support Level | $12.01 | $41.52 |
| Resistance Level | $25.58 | $49.46 |
| Average True Range (ATR) | 1.45 | 2.06 |
| MACD | -0.22 | 0.01 |
| Stochastic Oscillator | 73.77 | 15.81 |
Oscar Health Inc is a healthcare technology company built around a full stack technology platform and a relentless focus on serving its members. It offers Individual & Family plans and health technology solutions that power the healthcare industry. Oscar operates as one segment to sell insurance to individuals, families and employees through the federal and state-run healthcare exchanges formed in conjunction with the Patient Protection and Affordable Care Act (ACA) and leverages its technology platform to provide services via its Oscar offering.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.